Focal Epilepsy Study
Are you living with epilepsy?
If you have been diagnosed with focal epilepsy, our clinical trial may be able to help. We are studying an investigational drug to add on to your current epilepsy treatments. There is no cost to you to participate and insurance is not required.
Focal onset epilepsy, also called partial epilepsy, is the most common form of epilepsy.
Despite current therapies, a high unmet need exists for further seizure reduction with reduced side effects, for people who are still experiencing seizures while taking currently available anti-seizure medications. About 33% of adults fall into this group.
Biohaven is working with epileptologistsAn epileptologist is a neurologist who specializes in caring for people with epilepsy, and has completed an additional subspecialty training in epilepsy care. and neurologists in your area to research an investigational medication that may be able to help provide better seizure freedom with fewer side effects.
Who is the Study For?
If you or a loved one have been diagnosed with focal onset epilepsy, are between the ages of 18-75 and are still experiencing seizures while taking one or more anti-seizure medications, you may qualify for the Rise study.
We named this study “Rise” because we believe epilepsy should not stop you from living the life of your dreams.
Rise is a study to evaluate the efficacy, safety and tolerability of BHV-7000 in patients with focal onset epilepsy.
A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy
Criteria to Qualify:
Be 18 to 75 years of age- Have a diagnosis of focal epilepsy for at least 1 year
- Have at least 4 or more focal seizures monthly
- Have been unsuccessful with at least 2 anti-seizure medications and currently on a stable dose of at least 1 and up to 3 anti-seizure treatments